Aquestive Therapeutics is a pharmaceutical company focused on developing and commercializing products which use its proprietary PharmFilm® technology. Co.'s main commercialized licensed product is Suboxone®, a sublingual film formulation of buprenorphine and naloxone, for the treatment of opioid dependence. Co.'s two main assets within its proprietary central nervous system portfolio, focused on epilepsy include Sympazan®, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome; and Libervant, a buccally, or inside of the cheek, administered soluble film formulation of diazepam. The AQST stock yearly return is shown above.
The yearly return on the AQST stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AQST annual return calculation with any dividends reinvested as applicable (on ex-dates).
|